NL970014I2 - 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan. - Google Patents

4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan.

Info

Publication number
NL970014I2
NL970014I2 NL970014C NL970014C NL970014I2 NL 970014 I2 NL970014 I2 NL 970014I2 NL 970014 C NL970014 C NL 970014C NL 970014 C NL970014 C NL 970014C NL 970014 I2 NL970014 I2 NL 970014I2
Authority
NL
Netherlands
Prior art keywords
piperazinylpropyl
triazol
chlorophenyl
substituted
compounds
Prior art date
Application number
NL970014C
Other languages
English (en)
Other versions
NL970014I1 (nl
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22922879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL970014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NL970014I1 publication Critical patent/NL970014I1/nl
Publication of NL970014I2 publication Critical patent/NL970014I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL970014C 1981-03-16 1997-03-17 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan. NL970014I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/244,464 US4338317A (en) 1981-03-16 1981-03-16 Phenoxyethyl-1,2,4,-triazol-3-one antidepressants

Publications (2)

Publication Number Publication Date
NL970014I1 NL970014I1 (nl) 1997-06-02
NL970014I2 true NL970014I2 (nl) 1997-09-01

Family

ID=22922879

Family Applications (2)

Application Number Title Priority Date Filing Date
NL8201021A NL190757C (nl) 1981-03-16 1982-03-11 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan.
NL970014C NL970014I2 (nl) 1981-03-16 1997-03-17 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL8201021A NL190757C (nl) 1981-03-16 1982-03-11 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan.

Country Status (26)

Country Link
US (1) US4338317A (nl)
JP (1) JPS57159774A (nl)
KR (1) KR880001374B1 (nl)
AT (1) AT384022B (nl)
BE (1) BE892503A (nl)
CA (1) CA1198436A (nl)
CH (1) CH649539A5 (nl)
CY (1) CY1373A (nl)
DE (1) DE3209557A1 (nl)
DK (1) DK158728C (nl)
ES (1) ES8305756A1 (nl)
FI (1) FI73670C (nl)
FR (1) FR2501690B1 (nl)
GB (1) GB2096137B (nl)
GR (1) GR76076B (nl)
HK (1) HK4788A (nl)
IE (1) IE52788B1 (nl)
IT (1) IT1148137B (nl)
KE (1) KE3711A (nl)
LU (1) LU84011A1 (nl)
MX (1) MX9203176A (nl)
NL (2) NL190757C (nl)
SE (1) SE447256B (nl)
SG (1) SG30287G (nl)
YU (1) YU43256B (nl)
ZA (1) ZA821359B (nl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4386091A (en) * 1982-02-24 1983-05-31 Mead Johnson & Company 2-Phenoxyalkyl-1,2,4-triazol-3-one antidepressants
AT388555B (de) * 1983-06-29 1989-07-25 Bristol Myers Co Verfahren zur herstellung von neuen 1,2,4-triazol-3-on-derivaten
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
YU44721B (en) * 1983-11-30 1990-12-31 Bristol Myers Co Process for obtaining 4-(2-phenoxyethyl)-1,2,4-triazolone
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
IT1256387B (it) * 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
AU7025396A (en) 1995-10-17 1997-05-01 Bristol-Myers Squibb Company Nefazodone: treatment of panic attack
CA2182241C (en) * 1996-07-29 2002-09-17 Bo Lei Methods for the manufacture of nefazodone
US5854248A (en) * 1996-07-31 1998-12-29 Bristol-Myers Squibb Company Nefazodone: use in migraine prophylaxis
US5852020A (en) * 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder
US5735873A (en) * 1996-12-19 1998-04-07 Maclean; David S. Surgical tool handle
US5917050A (en) * 1998-02-11 1999-06-29 Bayer Corporation Process for preparing alkoxytriazolinones
ES2152860B1 (es) * 1998-10-23 2001-08-16 Finaf 92 Sa Forma cristalina de la nefazodona y procedimiento para su preparacion.
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6469008B2 (en) 1999-04-09 2002-10-22 Sepracor Inc. (R)-hydroxynefazodone antipsychotic therapy
AU4215400A (en) * 1999-04-09 2000-11-14 Sepracor, Inc. S-hydroxynefazodone
US6586437B2 (en) 1999-04-09 2003-07-01 Sepracor Inc. (S)-hydroxynefazodone antipsychotic therapy
CA2369732A1 (en) 1999-04-09 2000-10-19 Sepracor Inc. R-hydroxynefazodone
CA2356450C (en) 2001-09-10 2003-11-25 Brantford Chemicals Inc. An improved process for the preparation of nefazodone hydrochloride
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CA2523191A1 (en) * 2003-04-30 2004-11-18 Fmc Corporation Phenyl substituted cyclic derivatives
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
TW200612961A (en) * 2004-05-18 2006-05-01 Fmc Corp Substituted cyclic urea derivatives
EP1904843A2 (en) * 2005-07-08 2008-04-02 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
GB2454290B (en) * 2007-08-07 2009-09-30 Prosarix Ltd Novel serotonergic modulators
WO2009111031A2 (en) 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI368512B (en) * 2009-04-30 2012-07-21 Univ Kaohsiung Medical Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
CN104402842A (zh) * 2014-11-19 2015-03-11 苏州乔纳森新材料科技有限公司 一种哌嗪类药物中间体的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione

Also Published As

Publication number Publication date
SE8201631L (sv) 1982-09-17
DK158728B (da) 1990-07-09
IE52788B1 (en) 1988-03-02
HK4788A (en) 1988-01-29
IE820589L (en) 1982-09-16
NL970014I1 (nl) 1997-06-02
MX9203176A (es) 1992-07-01
FI73670B (fi) 1987-07-31
ZA821359B (en) 1983-01-26
DE3209557C2 (nl) 1993-07-15
FR2501690A1 (fr) 1982-09-17
AT384022B (de) 1987-09-25
ES510449A0 (es) 1983-04-16
US4338317A (en) 1982-07-06
YU52582A (en) 1985-06-30
DK158728C (da) 1990-12-03
KR830009089A (ko) 1983-12-17
CH649539A5 (de) 1985-05-31
NL190757C (nl) 1994-08-01
DK112582A (da) 1982-09-17
NL190757B (nl) 1994-03-01
LU84011A1 (fr) 1983-02-22
AU8117082A (en) 1982-09-23
GB2096137A (en) 1982-10-13
KE3711A (en) 1987-04-30
JPS57159774A (en) 1982-10-01
SG30287G (en) 1987-07-17
DE3209557A1 (de) 1982-12-09
GB2096137B (en) 1985-01-03
FI820856L (fi) 1982-09-17
FR2501690B1 (fr) 1985-07-05
GR76076B (nl) 1984-08-03
BE892503A (fr) 1982-09-15
IT1148137B (it) 1986-11-26
IT8247978A0 (it) 1982-03-12
YU43256B (en) 1989-06-30
KR880001374B1 (ko) 1988-07-29
ATA104582A (de) 1987-02-15
JPH0237353B2 (nl) 1990-08-23
NL8201021A (nl) 1982-10-18
ES8305756A1 (es) 1983-04-16
SE447256B (sv) 1986-11-03
CA1198436A (en) 1985-12-24
AU555888B2 (en) 1986-10-16
FI73670C (fi) 1987-11-09
CY1373A (en) 1987-08-07

Similar Documents

Publication Publication Date Title
NL190757C (nl) 4-(3-Chloorfenyl)-1-piperazinylpropyl gesubstitueerde-1,2,4-triazool-3-on verbindingen met antidepressieve werking en farmaceutische preparaten daarvan.
NL190664C (nl) Gesubstitueerde benzhydrylpiperidinoderivaten met therapeutische werking en farmaceutische preparaten die deze verbindingen bevatten.
NL190580C (nl) Gesubstitueerde benzhydrylpiperidinederivaten met therapeutische werking en preparaten die deze stoffen bevatten.
NL193981B (nl) 7-(eventueel gesubstitueerd naftyl)-3-methyl-octa-2,4,6-trieenderivaten met retineachtige werking alsmede farmaceutische en kosmetische preparaten die dergelijke derivaten bevatten.
DE3580304D1 (de) Arzneimittel.
NL194239B (nl) Dialkoxyfosfinolmethylbenzamideverbindingen en farmaceutische preparaten, die deze bevatten.
NL7810520A (nl) Nieuwe 2,6-diaminonebularinen, alsmede farmaceutische preparaten die deze verbindingen bevatten.
NL193819B (nl) Naftaleenderivaten alsmede farmaceutische en cosmetische preparaten, die deze derivaten bevatten.
NL192343B (nl) 17Ó-gesubstitueerde androsta-(1,)4-(di)een-3-on-17ß-carbonzuurverbindingen met een ontstekingswerende werkzaamheid en farmaceutische preparaten, die deze verbindingen bevatten.
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
NL990010I1 (nl) Ä3HÜ-imidazo-Ä5,1-dÜ-1,2,3,5-tetrazine-4-on derivaten en farmaceutische samenstellingen, die deze derivaten bevatten.
NL188576C (nl) Carbamoyloxazolidonderivaten met pesticide werking alsmede acaricide preparaten, die dergelijke verbindingen bevatten.
NL191307C (nl) Analgetisch werkzame piperazinederivaten en farmaceutische preparaten, die deze derivaten bevatten.
FI882737A (fi) Foerfarande foer framstaellning av n-(aryl-, aryloxi-, aryltio-arylsulfinyl och -arylsulfonyl)-alkyl-n,n'- (eller n'n')-alkylamino-alkyl-urea och -cyanoguanidin.
DE3880227D1 (de) Vorbeugung der nachoxidaton von methacrolein.
DE3576505D1 (de) 3,4-dihydrobenzopyranverbindungen und diese enthaltende pharmazeutische zusammenstellungen.
FI865347A (fi) Gonadoliberinderivat som innehaoller en aromatisk aminokarbozylsyra i position 6, farmaceutiska och veterinaera preparat innehaollande dessa och foerfarande foer framstaellning daerav.
FI853369L (fi) Ny -glukosidasinhibitor, foerfarande foer framstaellning av denna, anvaendning av denna och farmaceutiska preparat.
IT8721990A0 (it) Composizione ad uso topico avente attivita' tricogena, antiforfora ed antiseborroica.
IT8722218A0 (it) Ftalazino derivati ad attivita'farmaceutica.
IT8621194A0 (it) Azolilderivati ad attivita'antifungina.
IT8720707A0 (it) Impiego del 2,4-monofurfuriliden-sorbitolo ad uso cosmetico.
IT8121960A0 (it) Composti ad attivita' gaba simile, procedimento per prepararli e composizioni farmaceutiche cheli comprendono.
IT8121298A0 (it) Nitroimidazoli ad attivita'tricomonacida, procedimento per laloro preparazione e relative composizioni farmaceutiche.
FR2677477B1 (fr) Nouveaux derives de l'oxazole leur preparation, leur utilisation et les compositions pharmaceutiques qui les contiennent.